spinal stenosis: Narrowing of the spinal canal.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
271 |
4. Check minimum number of eventsNone |
271 |
5. Include endpointsNone |
271 |
6. Filter based on genotype QC (FinnGen only) |
271 |
Control definitions (FinnGen only)
- Control exclude
- M13_DORSOPATHY
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- M48
- Name in latin
- Vertebra collapsa non alibi classificata
Similar endpoints
↥List of similar endpoints to
Collapsed vertebra, not elsewhere classified
based on the number of shared cases.
Similar with more cases:
- Spondylopathies
- Dorsopathies
- Diseases of the musculoskeletal system and connective tissue
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 2977 | 1951 | 1011 |
| Only index persons | 2606 | 1732 | 874 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.05 | 0.06 | 0.03 |
| Only index persons | 0.05 | 0.06 | 0.03 |
| Median age at first event (years) | |||
| Whole population | 76.32 | 78.64 | 71.80 |
| Only index persons | 76.04 | 78.45 | 71.27 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 271 | 178 | 93 |
| Unadjusted period prevalence (%) | 0.05 | 0.06 | 0.04 |
| Median age at first event (years) | 73.22 | 74.06 | 71.60 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 243
- Matched controls
- 2428
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M48.5
ICD-10 Finland
Collapsed vertebra, not elsewhere classified
+∞
323.0
243
*
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
24.9
48.1
69
38
M54.5
ICD-10 Finland
Low back pain
8.1
43.2
118
252
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
8.7
39.6
98
175
M48.0
ICD-10 Finland
Spinal stenosis
36.0
36.8
47
16
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
39.8
34.5
43
13
H05BA01
ATC
calcitonin (salmon synthetic); nasal, parenteral
13.9
33.6
60
56
N02AX02
ATC
tramadol; systemic, rectal
5.3
32.5
145
530
M54.9
ICD-10 Finland
Dorsalgia, unspecified
14.8
30.8
53
45
M51.1
ICD-10 Finland
Lumbar and other intervertebral disc disorders with radiculopathy
43.3
30.3
37
10
S32.0
ICD-10 Finland
Fracture of lumbar vertebra
19.3
30.0
46
29
M80.9
ICD-10 Finland
Unspecified osteoporosis with pathological fracture
24.9
28.5
40
19
S22.0
ICD-10 Finland
Fracture of thoracic vertebra
27.0
28.5
39
17
N03AX16
ATC
pregabalin; oral
6.1
27.8
88
207
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
4.5
27.2
152
656
N03AX12
ATC
gabapentin; oral
8.8
26.8
61
89
NA2AA
NOMESCO Finland
Thoracal spine X-ray examination without contrast
32.7
26.2
34
12
N02AA05
ATC
oxycodone; systemic
5.5
25.9
90
234
M47.2
ICD-10 Finland
Other spondylosis with radiculopathy
120.4
20.9
22
*
ABC36
NOMESCO Finland
Decompression of lumbar nerve roots
216.9
19.9
20
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.6
19.9
150
754
M81.9
ICD-10 Finland
Osteoporosis, unspecified
8.9
19.7
43
57
M54.4
ICD-10 Finland
Lumbago with sciatica
8.3
19.2
44
63
M05BA04
ATC
alendronic acid; oral
5.1
19.1
67
169
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
3.8
18.8
103
396
M80.0
ICD-10 Finland
Postmenopausal osteoporosis with pathological fracture
14.6
18.5
31
24
NK6QA
NOMESCO Finland
Measurement of bone density from tow or more locations with X-ray
8.9
18.0
39
51
NA3CG
NOMESCO Finland
Lumbar spine extensive MRI examination with high intensity magnet
45.8
17.6
21
5
M54.6
ICD-10 Finland
Pain in thoracic spine
14.9
17.0
28
21
L03
ICPC
Low back symptom/complaint
4.1
16.9
75
237
W01
ICD-10 Finland
Fall on same level from slipping, tripping and stumbling
3.2
16.5
126
608
318
Kela drug reimbursment
Teriparatide
64.5
16.0
18
*
N02AA59
ATC
codeine, combinations excl. psycholeptics; systemic
3.1
15.7
121
584
M51.3
ICD-10 Finland
Other specified intervertebral disc degeneration
34.2
15.0
19
6
M05BX04
ATC
denosumab; parenteral
6.2
14.4
40
75
H05AA02
ATC
teriparatide; parenteral
79.7
13.7
15
*
A02BC02
ATC
pantoprazole; systemic
3.0
13.7
176
1140
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
6.4
13.5
36
64
N02BE01
ATC
paracetamol; systemic, rectal
4.5
13.5
223
1726
M03BX02
ATC
tizanidine; oral
2.8
13.4
139
781
N02AJ06
ATC
codeine and paracetamol; systemic
3.0
12.4
91
409
C90.0
ICD-10 Finland
Multiple myeloma
19.3
12.2
18
10
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
3.1
11.8
74
297
NA3AD
NOMESCO Finland
Lumbar spine and sacrum CT examination
20.2
11.8
17
9
L95
ICPC
Osteoporosis
6.9
11.6
29
47
C03CA01
ATC
furosemide; systemic
2.6
11.6
129
735
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.8
11.6
97
468
9732/3-C42.1
ICD-O-3
Plasma cell myeloma of bone marrow
26.5
11.3
15
6
X59
ICD-10 Finland
Exposure to unspecified factor
3.3
11.3
62
226
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
3.3
10.9
60
218
R53
ICD-10 Finland
Malaise and fatigue
3.0
10.8
73
306
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
2.7
10.8
95
469
C07AB07
ATC
bisoprolol; oral
2.5
10.7
157
1023
153
Kela drug reimbursment
Lenalidomid
62.8
10.7
12
*
L04AX04
ATC
lenalidomide; oral
62.8
10.7
12
*
NA3EA
NOMESCO Finland
Lumbar spine X-ray examination with flexion
+∞
10.5
10
*
N06AX21
ATC
duloxetine; oral
5.3
10.2
31
65
Z01.8
ICD-10 Finland
Other specified special examinations
3.0
10.2
66
267
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
4.0
10.1
42
121
M79.6
ICD-10 Finland
Pain in limb
2.6
10.0
91
453
UJF32
NOMESCO Finland
Coloscopy
2.7
9.9
80
371
B01AB05
ATC
enoxaparin; parenteral
2.5
9.9
98
513
M01AH05
ATC
etoricoxib; oral
2.4
9.7
127
764
N06AX11
ATC
mirtazapine; oral
2.6
9.5
90
453
NB1AA
NOMESCO Finland
Shoulder X-ray examination without contrast
4.6
9.5
33
80
A02BC05
ATC
esomeprazole; systemic
2.4
9.5
109
613
M43.1
ICD-10 Finland
Spondylolisthesis
31.4
9.5
12
*
NA2BG
NOMESCO Finland
Thoracal spine MRI examination with high intensity magnet
103.9
9.5
10
*
M54
ICD-10 Finland
Dorsalgia
4.3
9.4
35
91
A02BC01
ATC
omeprazole; systemic
2.5
9.4
93
483
R07.4
ICD-10 Finland
Chest pain, unspecified
2.6
9.3
87
434
NE1AA
NOMESCO Finland
Pelvis X-ray examination
4.5
9.3
33
82
L02
ICPC
Back symptom/complaint
4.5
9.1
32
79
X58
ICD-10 Finland
Exposure to other specified factors
3.8
9.0
39
117
A49.9
ICD-10 Finland
Bacterial infection, unspecified
3.4
9.0
45
152
R52.2
ICD-10 Finland
Other chronic pain
9.2
9.0
18
21
A02BA02
ATC
ranitidine; systemic
2.7
8.9
71
325
M01AH02
ATC
rofecoxib; oral
3.1
8.8
52
194
A02BC03
ATC
lansoprazole; oral
2.5
8.8
88
453
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
2.8
8.6
62
267
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
5.0
8.6
27
59
M51.8
ICD-10 Finland
Other specified intervertebral disc disorders
93.2
8.5
9
*
ABC56
NOMESCO Finland
Decompression of lumbar spinal canal and nerve roots
+∞
8.4
8
*
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.9
8.4
55
224
C01DA08
ATC
isosorbide dinitrate; oral, oral aerosol, sublingual, transdermal
2.4
8.3
89
477
XW000
NOMESCO Finland
Bone marrow biopsy
6.3
8.2
21
36
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
13.6
8.0
13
10
A04AA01
ATC
ondansetron; systemic, rectal
4.5
7.9
27
65
NA1AA
NOMESCO Finland
Cervical spine X-ray examination without contrast
11.3
7.9
14
13
L28
ICPC
Limited function/disability (L)
2.7
7.8
60
267
D64.9
ICD-10 Finland
Anaemia, unspecified
3.2
7.8
43
154
K21.0
ICD-10 Finland
Gastro-oesophageal reflux disease with oesophagitis
3.8
7.7
32
93
J01DB01
ATC
cefalexin; oral
2.3
7.5
191
1482
Z46.9
ICD-10 Finland
Fitting and adjustment of unspecified device
13.9
7.5
12
9
M80.8
ICD-10 Finland
Other osteoporosis with pathological fracture
82.5
7.5
8
*
NA2CG
NOMESCO Finland
Thoracal spine extensive MRI examination with high intensity magnet
82.5
7.5
8
*
Z04.8
ICD-10 Finland
Examination and observation for other specified reasons
3.5
7.3
34
108
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
3.3
7.3
36
120
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
5.4
7.3
21
42
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.2
7.3
40
142
M03BC01
ATC
orphenadrine (citrate); systemic
3.0
7.3
44
166
M47.82
ICD-10 Finland
Other spondylosis, cervical region
16.4
7.3
11
7
I48
ICD-10 Finland
Atrial fibrillation and flutter
2.2
7.3
94
539
H02AB06
ATC
prednisolone; systemic
2.1
7.2
119
759
A28
ICPC
Limited function/disability NOS
2.5
7.2
63
299
A06AD11
ATC
lactulose; oral
2.5
7.2
63
300
R52.9
ICD-10 Finland
Pain, unspecified
3.8
7.0
29
84
ZZH21
NOMESCO Finland
Graft of patients own bone, small pieces
14.3
7.0
11
8
L86
ICPC
Back syndrome with radiating pain
6.4
6.9
17
28
N05BA04
ATC
oxazepam; oral
2.3
6.9
73
380
SPAT1148
SPAT
Treatment of chronic ulcer or burn
2.7
6.8
51
220
M80.5
ICD-10 Finland
Idiopathic osteoporosis with pathological fracture
41.2
6.8
8
*
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
5.3
6.7
19
38
AA1AD
NOMESCO Finland
CT of head and brain
2.2
6.6
79
437
NA1AD
NOMESCO Finland
Cervical spine CT examination
6.0
6.6
17
30
S22.3
ICD-10 Finland
Fracture of rib
3.8
6.6
27
78
D07AC01
ATC
betamethasone; topical
2.1
6.5
89
520
I25.1
ICD-10 Finland
Atherosclerotic heart disease
2.2
6.5
78
433
M80.4
ICD-10 Finland
Drug-induced osteoporosis with pathological fracture
71.7
6.5
7
*
NA3DG
NOMESCO Finland
Lumbar spine very extensive MRI examination with high intensity magnet
71.7
6.5
7
*
NAG62
NOMESCO Finland
Posterior fusion of lumbar spine with fixation, 2-3 vertebraea
+∞
6.3
6
*
N30.0
ICD-10 Finland
Acute cystitis
2.6
6.2
48
212
ND2AA
NOMESCO Finland
Hand and fingers X-ray examination
3.9
6.2
24
66
N03AE01
ATC
clonazepam; systemic
4.4
6.2
21
51
G04CA02
ATC
tamsulosin; oral
2.4
6.2
57
277
ZX120
NOMESCO Finland
Intravenous
3.1
6.1
32
112
R10.1
ICD-10 Finland
Pain localized to upper abdomen
2.6
6.1
45
195
M05BA07
ATC
risedronic acid; oral
4.3
6.1
21
52
WYA30
NOMESCO Finland
Preparations for expected poor cooperation
3.7
6.0
25
73
M54.8
ICD-10 Finland
Other dorsalgia
7.6
6.0
13
18
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
35
72
5.43
16.66
16.1
3.7
62.3
69.9
mg/l
0.05
27
56
35
72
5.43
16.66
15.9
3.7
84.8
87.0
mg/l
0.02
27
56
121
593
2.88
15.98
5.1
3.1
0.3
0.5
e6/l
0.67
98
457
182
1105
2.97
15.97
13.9
5.9
1.2
1.2
mmol/l
0.91
152
902
150
843
2.75
14.93
3.1
2.2
80.4
78.6
nmol/l
0.31
136
711
75
298
3.10
14.26
3.6
2.3
20.2
21.0
%
0.17
66
248
81
337
3.00
14.20
3.7
2.3
11.2
12.0
umol/l
0.40
74
298
78
318
3.04
14.17
3.5
2.3
2.2
2.3
g/l
0.82
72
282
171
1046
2.72
14.07
9.5
5.9
10.8
12.5
umol/l
1.29
157
980
112
559
2.71
13.88
2.8
2.2
3.2
3.3
mg/l
0.07
89
464
139
773
2.64
13.82
5.8
3.1
—
—
—
0
0
84
367
2.87
13.38
2.5
1.8
—
—
—
0
0
157
953
2.54
12.63
7.1
3.9
33.4
34.8
g/l
1.79
138
861
160
991
2.50
12.16
14.7
5.2
1.2
1.2
mmol/l
1.34
150
865
159
983
2.49
12.11
6.1
4.0
0.0
0.0
estimate
0.00
28
182
64
256
2.96
11.85
2.2
1.8
—
—
—
0
0
134
776
2.44
11.67
3.8
3.2
2327.5
2008.1
ng/l
0.21
113
657
111
591
2.49
11.62
3.3
2.3
49.7
58.2
u/l
2.41
98
533
131
755
2.42
11.48
4.4
3.0
2.3
2.4
mmol/l
2.91
118
644
135
790
2.41
11.41
4.2
2.6
136.7
132.0
ug/l
0.10
118
698
73
324
2.72
11.06
5.3
3.0
4.7
3.0
e6/l
0.39
39
182
63
259
2.87
11.04
2.2
1.7
—
—
—
0
0
53
200
3.05
10.81
5.4
2.1
7.2
10.5
umol/l
0.92
44
173
157
999
2.36
10.75
6.6
4.2
0.0
0.0
estimate
0.00
28
177
157
1000
2.36
10.71
9.4
5.8
0.0
0.0
estimate
0.00
28
176
213
1559
2.71
10.59
14.8
6.8
81.6
80.8
u/l
0.09
200
1416
72
334
2.57
9.88
4.3
2.8
1.1
1.4
e6/l
0.39
39
190
167
1116
2.29
9.85
18.0
8.7
4.5
4.2
e9/l
0.69
143
973
45
168
3.01
9.30
2.3
1.5
—
—
—
0
0
32
97
3.61
9.22
1.7
1.7
0.3
5.5
ug/l
1.01
24
81
57
248
2.64
8.84
10.1
5.9
1.6
1.6
mmol/l
0.01
50
198
73
359
2.41
8.74
1.3
1.2
1.6
1.1
u/ml
0.26
18
82
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
27
77
3.78
8.49
4.1
2.1
0.4
0.4
u/ml
0.04
17
45
197
1461
2.28
8.36
6.1
3.9
19.8
15.2
mm/h
1.96
180
1296
172
1219
2.13
8.06
10.5
4.4
6.9
6.8
mmol/l
0.24
162
1129
42
165
2.83
7.88
1.8
2.1
330.9
400.1
nmol/l
0.94
36
147
97
561
2.14
7.76
4.4
2.7
34.7
32.6
u/l
0.13
87
541
31
103
3.27
7.75
14.0
1.7
3.5
3.6
g/l
0.10
25
73
31
104
3.24
7.63
14.0
1.7
—
—
—
0
0
31
104
3.24
7.63
14.0
1.7
7.3
7.6
g/l
0.39
26
76
106
639
2.08
7.56
2.7
1.9
251.7
202.2
u/l
0.16
95
593
31
106
3.17
7.40
3.0
3.9
1.4
2.5
mmol/l
0.64
22
86
133
881
2.00
7.23
6.3
3.8
50.5
81.0
ng/l
0.36
109
668
88
504
2.10
7.13
2.3
1.8
1107.4
1084.5
nmol/l
0.08
64
367
157
1111
1.98
6.97
4.4
2.8
65.9
51.7
u/l
1.05
141
994
12
20
6.23
6.96
2.7
3.2
—
—
—
0
0
139
947
1.96
6.85
2.6
2.1
91.8
94.8
pmol/l
0.24
74
454
43
185
2.57
6.75
2.6
2.0
32.9
29.4
u/l
0.37
36
154
39
161
2.66
6.64
2.1
1.6
—
—
—
0
0
24
77
3.32
6.34
17.2
1.9
0.0
0.0
g/l
0.00
24
66
132
903
1.90
6.26
2.6
2.4
—
—
—
0
0
41
179
2.52
6.23
4.0
3.2
78.8
82.2
ng/l
0.11
31
147
131
895
1.90
6.22
5.5
3.8
—
—
—
0
0
24
78
3.28
6.21
17.2
1.9
0.0
0.0
g/l
0.00
24
66
77
446
2.01
5.91
5.7
3.5
168.1
258.6
ng/l
0.39
68
378
19
55
3.64
5.84
1.6
1.4
—
—
—
0
0
28
105
2.86
5.70
2.2
1.8
1.4
1.6
%
0.81
22
90
91
569
1.90
5.54
2.1
1.5
20.0
21.0
nmol/l
0.26
79
461
81
490
1.93
5.43
3.6
2.3
—
—
—
0
0
17
48
3.71
5.42
1.3
1.4
—
—
—
0
0
17
48
3.71
5.42
1.3
1.4
—
—
—
0
0
32
133
2.59
5.37
2.2
1.4
—
—
—
0
0
15
39
4.01
5.34
1.5
1.2
—
—
—
0
0
230
1951
2.18
5.15
39.2
15.3
25.8
25.5
mg/l
0.05
211
1589
19
60
3.33
5.15
1.3
1.8
—
—
—
0
0
15
43
3.63
4.68
1.9
1.8
—
—
—
0
0
54
299
2.01
4.62
1.3
1.2
25.9
39.4
iu/ml
0.66
19
102
41
210
2.12
4.30
2.3
2.3
5.8
6.5
ug/l
0.14
31
176
16
51
3.27
4.28
1.9
1.8
—
—
—
0
0
72
451
1.81
4.22
4.9
2.9
2.5
2.5
mmol/l
0.04
67
398
16
52
3.21
4.15
1.8
1.8
—
—
—
0
0
10
23
4.48
4.12
1.6
1.7
—
—
—
0
0
13
37
3.64
4.10
3.2
2.3
15.4
16.1
%
—
5
20
48
266
1.98
4.08
1.2
1.2
52.6
17.6
u/ml
0.48
11
88
40
208
2.08
4.04
7.3
3.1
3.5
2.1
mmol/l
1.83
35
165
20
76
2.76
3.99
3.8
3.2
0.8
0.8
nmol/l
0.10
14
58
109
783
1.66
3.86
7.7
4.4
—
—
—
0
0
11
29
3.91
3.84
1.5
1.7
—
—
—
0
0
11
29
3.91
3.84
1.5
1.7
—
—
—
0
0
12
34
3.65
3.81
1.4
1.7
—
—
—
0
0
203
1713
1.74
3.78
41.9
17.4
36.5
38.0
%
1.01
125
1076
6
5
12.23
3.78
1.2
1.0
—
—
—
0
0
8
13
6.30
3.52
1.4
1.5
—
—
—
0
0
11
32
3.54
3.37
1.5
1.7
—
—
—
0
0
15
54
2.88
3.31
1.4
1.3
—
—
—
0
0
18
72
2.61
3.28
2.1
1.2
—
—
—
0
0
10
28
3.67
3.22
1.6
1.7
—
—
—
0
0
47
280
1.82
3.20
13.8
5.7
102.1
104.6
mmol/l
1.82
47
269
7
11
6.50
3.20
1.7
1.8
—
—
—
0
0
64
422
1.68
3.06
2.2
1.7
1.5
1.5
mg/l
0.02
54
336
7
12
5.96
3.04
1.7
1.8
—
—
—
0
0
8
17
4.81
2.94
2.1
1.5
—
—
—
0
0
67
452
1.64
2.93
7.0
4.4
1.0
1.0
kg/l
0.83
21
76
16
64
2.59
2.93
1.5
1.2
—
—
—
0
0
72
496
1.62
2.90
4.9
3.0
7570.0
8615.5
umol/l
0.05
63
422
16
65
2.55
2.84
1.5
1.2
—
—
—
0
0
9
23
4.01
2.80
1.3
1.7
—
—
—
0
0
231
2082
1.74
2.70
20.0
10.2
21.8
23.2
u/l
0.87
218
1975
8
19
4.30
2.70
1.3
1.1
—
97.2
—
0
5
17
74
2.38
2.64
2.1
3.0
—
—
—
0
0
7
15
4.76
2.61
1.7
1.6
—
—
—
0
0
231
2087
1.72
2.61
43.8
18.4
138.7
139.6
mmol/l
4.23
221
2015
231
2088
1.72
2.59
45.0
18.5
4.0
4.0
mmol/l
0.09
221
2013
73
517
1.56
2.59
1.9
1.8
416.0
439.9
pmol/l
0.24
57
401
39
235
1.77
2.56
6.1
3.3
—
—
—
0
0
21
102
2.15
2.55
7.5
3.3
26.2
24.1
mmol/l
2.39
21
96
5
8
6.34
2.38
1.0
1.0
—
—
—
0
0
10
35
2.93
2.33
1.3
1.4
—
—
—
0
0
10
35
2.93
2.33
1.4
1.5
—
—
—
0
0
5
9
5.64
2.22
2.6
1.3
197.0
214.8
u/l
—
5
9
5
9
5.64
2.22
1.4
1.0
—
—
—
0
0
5
9
5.64
2.22
1.2
1.2
—
—
—
0
0
8
24
3.40
2.19
2.0
2.1
—
—
—
0
0
8
24
3.40
2.19
1.6
1.3
—
—
—
0
0
8
25
3.26
2.11
1.4
1.2
—
—
—
0
0
234
2153
1.64
2.07
53.9
22.9
126.0
131.3
g/l
5.55
227
2103
17
83
2.12
2.06
1.5
1.3
—
—
—
0
0
6
16
3.81
1.94
2.0
1.9
—
—
—
0
0
206
1856
1.46
1.89
34.1
15.3
72.5
71.9
ml/min/173m2
0.14
179
1517
171
1494
1.39
1.85
5.1
3.9
15.6
15.2
pmol/l
0.98
158
1290
7
24
2.97
1.73
3.9
4.3
—
—
—
0
0
7
24
2.97
1.73
2.0
2.1
—
—
—
0
0
5
14
3.62
1.62
4.0
1.4
—
—
—
0
0
5
14
3.62
1.62
1.2
1.9
—
—
—
0
0
5
14
3.62
1.62
1.2
1.9
—
—
—
0
0
31
201
1.61
1.60
3.2
1.8
0.2
0.2
g/l
0.11
25
190
203
1850
1.39
1.54
7.0
6.2
42.1
40.9
mmol/mol
0.71
185
1664
11
51
2.21
1.52
1.3
1.3
—
—
—
0
0
7
27
2.63
1.52
2.6
1.4
—
—
—
0
0
7
27
2.63
1.52
2.6
1.4
—
—
—
0
0
7
27
2.63
1.52
2.6
1.4
—
—
—
0
0
7
27
2.63
1.52
2.6
1.4
—
—
—
0
0
7
28
2.54
1.46
2.6
1.4
—
—
—
0
0
6
22
2.76
1.44
1.3
1.1
—
—
—
0
0
30
201
1.55
1.37
1.4
1.4
—
—
—
0
0
5
17
2.98
1.36
1.2
1.7
—
—
—
0
0
198
1813
1.34
1.34
6.1
4.8
1.9
2.1
mu/l
0.95
184
1570
211
1956
1.36
1.27
5.0
5.1
2.4
2.6
mmol/l
1.85
185
1732
64
504
1.35
1.27
5.7
5.2
3.9
2.6
ug/l
0.59
54
439
6
25
2.43
1.25
1.2
1.2
—
—
—
0
0
203
1874
1.33
1.24
4.4
4.5
1.5
1.5
mmol/l
0.41
176
1647
69
553
1.33
1.22
7.5
4.2
0.0
0.0
estimate
0.00
28
174
21
134
1.61
1.18
2.1
3.4
58.7
53.1
ml/min/173m2
—
9
66
16
96
1.71
1.13
3.1
1.9
—
—
—
0
0
204
1895
1.31
1.12
4.4
4.5
4.3
4.5
mmol/l
1.55
179
1683
196
1816
1.29
1.06
4.0
4.0
1.3
1.3
mmol/l
0.43
164
1578
38
287
1.38
0.98
3.1
3.0
0.7
0.9
ug/l
0.40
26
201
5
23
2.20
0.98
2.4
2.0
—
—
—
0
0
5
23
2.20
0.98
2.4
2.0
—
—
—
0
0
5
23
2.20
0.98
2.4
2.0
—
—
—
0
0
6
27
2.25
0.94
2.8
1.4
—
—
—
0
0
14
86
1.66
0.93
2.4
1.6
—
—
—
0
0
8
44
1.84
0.86
2.5
1.3
—
—
—
0
0
13
80
1.66
0.86
1.1
1.1
—
—
—
0
0
8
45
1.80
0.85
1.0
1.2
—
—
—
0
0
49
402
1.27
0.74
4.3
4.4
21.3
21.6
%
0.04
23
206
203
1932
1.20
0.63
5.2
4.9
6.1
6.1
mmol/l
0.02
181
1686
8
49
1.65
0.62
1.1
1.1
—
17.0
—
0
5
33
267
1.27
0.57
16.8
7.6
—
—
—
0
0
6
36
1.68
0.57
1.3
1.4
—
—
—
0
0
8
55
1.47
0.56
1.8
1.3
—
—
—
0
0
5
37
1.36
0.37
2.6
1.2
1.1
0.9
nmol/l
—
5
29
46
503
0.90
0.24
1.5
1.6
1.4
1.3
mmol/l
0.29
39
388
25
285
0.86
0.24
4.5
4.5
33.6
32.8
%
0.14
16
166
5
41
1.22
0.22
1.0
1.1
—
—
—
0
0
5
41
1.22
0.22
1.8
1.1
—
—
—
0
0
5
42
1.19
0.21
1.4
2.2
—
—
—
0
0
5
42
1.19
0.21
1.8
1.2
—
2.1
—
0
5
0
11
0.00
0.21
0.0
1.3
—
—
—
0
0
0
14
0.00
0.20
0.0
1.2
—
—
—
0
0
0
14
0.00
0.20
0.0
1.2
—
—
—
0
0
0
14
0.00
0.20
0.0
1.3
—
—
—
0
0
7
58
1.21
0.18
2.0
1.8
—
—
—
0
0
23
213
1.09
0.09
1.3
1.3
—
—
—
0
0
5
54
0.92
0.00
2.4
1.4
—
—
—
0
0
7
70
1.00
0.00
2.0
1.9
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
6
68
0.88
0.00
3.0
3.7
39.0
25.9
mg/l
—
6
42
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
5
50
1.00
0.00
1.4
1.4
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint M13_VERTEBCOLLAPSE and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_VERTEBCOLLAPSE | 1.885 [1.61, 2.21] | < 0.001 |
| Birth year | 0.996 [0.99, 1.0] | 0.355 |
During the follow-up period (1.1.1998 — 31.12.2019), 934 out of 1714 females with M13_VERTEBCOLLAPSE died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_VERTEBCOLLAPSE | 2.57 [1.93, 3.42] | < 0.001 |
| Birth year | 0.987 [0.98, 1.0] | 0.008 |
During the follow-up period (1.1.1998 — 31.12.2019), 507 out of 886 males with M13_VERTEBCOLLAPSE died.
Mortality risk
Mortality risk for people of age
years, who have M13_VERTEBCOLLAPSE.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.216% | 0.475% |
| 5 | 1.281% | 3.061% |
| 10 | 3.045% | 7.447% |
| 15 | 5.762% | 13.539% |
| 20 | 9.692% | 22.336% |
Relationships between endpoints
↥Index endpoint: M13_VERTEBCOLLAPSE – Collapsed vertebra, not elsewhere classified
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data